Affiliate disclosure: some links on this page are affiliate links and may earn us a commission at no extra cost to you — it never affects our rankings or reviews.
Guide · Safety · United States
Are peptides safe? What the FDA has said, peptide by peptide
It depends on the peptide and on where it comes from. FDA-approved peptide medicines have been reviewed by the FDA for the uses on their labels, and their labels set out the risks. Compounded peptides are not FDA approved, and the FDA says it does not review compounded drugs for safety, effectiveness or quality before they are marketed[2]. For many peptides sold online, the FDA has said it has little or no safety information in people.[1]
This page reports what the FDA and HHS have said, quoted and dated. It does not judge any peptide safe or unsafe, and it is not medical advice: whether a treatment suits you is a decision for a licensed clinician. Sources checked November 17, 2026.
FDA-approved peptide medicines
A handful of peptides are FDA-approved prescription medicines, among them semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Approval means the FDA reviewed the evidence for the specific uses on the label. It does not mean a medicine has no risks: the labels list them. Wegovy and Zepbound, for example, each carry a boxed warning about a risk of thyroid C-cell tumors[5][4]. The full list of approved peptides, with the record behind each, is on our guide are peptides legal in the US.
Compounded peptides
A compounded peptide is made by a pharmacy for an individual prescription. The FDA says "compounded drugs are not FDA approved" and that it "does not review compounded drugs for safety, effectiveness or quality before they are marketed"[2]. For compounded GLP-1 medicines, it has received "multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors", where patients measured and injected the wrong dose[2].
For six peptides, BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon, the position changed in October 2026. No FDA-approved product exists for these six. Since October 2026 an interim HHS policy lets licensed 503A pharmacies compound them on a patient-specific prescription, by the route listed. HHS says the policy does not grant FDA approval or establish safety and effectiveness, and that it may revisit it.[3]
What the FDA has said about each peptide
The FDA lists bulk substances it says "may present significant safety risks" when used in compounding, with its reasons[1]. These are its stated concerns, quoted. Six of these peptides were later covered by the HHS interim policy, which does not establish their safety; the right-hand column gives each one's US status today.
| Peptide | What the FDA said | US status today |
|---|---|---|
| BPC-157 | May "pose risk for immunogenicity for certain routes of administration"; the FDA said it "has identified no, or only limited, safety-related information". | Covered by the HHS interim compounding policy (October 2026); not FDA approved |
| TB-500 | A risk of immunogenicity from "the potential for aggregation as well as peptide-related impurities"; the FDA said it "lacks important information regarding any safety issues raised by this drug". | Covered by the HHS interim compounding policy (October 2026); not FDA approved |
| MOTS-c | A risk of immunogenicity "for certain routes of administration"; the FDA "has not identified any human exposure data on drug products containing MOTs-C". | Covered by the HHS interim compounding policy (October 2026); not FDA approved |
| KPV | The FDA "has not identified any human exposure data on drug products containing KPV" and "lacks important information regarding any safety issues raised by KPV". | Covered by the HHS interim compounding policy (October 2026); not FDA approved |
| Semax | A risk of immunogenicity "due to the potential for aggregation and peptide-related impurities"; the FDA "has no, or limited, safety-related information for proposed routes of administration". | Covered by the HHS interim compounding policy (October 2026); not FDA approved |
| Epitalon | A risk of immunogenicity "due to the potential for aggregation and peptide-related impurities"; the FDA "has not identified safety-related information regarding epitalon for the proposed route of administration". | Covered by the HHS interim compounding policy (October 2026); not FDA approved |
| Ipamorelin | A risk of immunogenicity "for certain routes of administration"; a published study identified "serious adverse events including death" with intravenous use, and the FDA "lacks sufficient information to know whether the drug would cause harm". | No FDA-approved product; not covered by the HHS policy |
| CJC-1295 | A risk of immunogenicity; the FDA identified "serious adverse events associated with CJC-1295 including increased heart rate" and said "Available clinical data are limited". | No FDA-approved product; not covered by the HHS policy |
| AOD-9604 | A risk of immunogenicity "for certain routes of administration"; the FDA "has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear". | No FDA-approved product; not covered by the HHS policy |
| GHK-Cu (injected) | A risk of immunogenicity "due to the potential for aggregation and peptide-related impurities"; "There are limited data in humans to inform safety-related considerations". | No FDA-approved product; not covered by the HHS policy |
| Selank | A risk of immunogenicity "due to the potential for aggregation and peptide-related impurities"; the FDA "lacks important information regarding any safety issues raised by selank acetate administered to humans". | No FDA-approved product; not covered by the HHS policy |
| DSIP | A risk of immunogenicity "for certain routes of administration"; the FDA "has not identified safety-related information regarding emideltide for the proposed route of administration". | No FDA-approved product; not covered by the HHS policy |
| Melanotan II | A risk of immunogenicity "due to the potential for aggregation or peptide-related impurities"; "Published case reports discuss serious adverse events including melanoma". | Not covered by the HHS policy |
"Immunogenicity" means the body may mount an immune response to the peptide. "Peptide-related impurities" are unwanted by-products of making it.
Peptides sold online "for research"
The FDA warns that "Counterfeit drugs claim to be authentic, but could contain the wrong ingredients", and that some products are falsely labeled "for research purposes" or "not for human consumption". It "urges consumers not to purchase these products which are of unknown quality and may be harmful to their health"[2]. A product sold that way is not an approved medicine for people.
Questions to ask before any peptide treatment
- Is it an FDA-approved medicine, or compounded? If compounded, which state-licensed pharmacy makes it?
- Who prescribes it, and is that clinician licensed in my state?
- What does its label, or the FDA, say about its risks, and how will side effects be followed up?
More on what peptide therapy is and how it is prescribed: what is peptide therapy. For BPC-157 and the other five policy peptides: BPC-157 on prescription.
Frequently asked questions
Are peptides safe?
It depends on the peptide and where it comes from. FDA-approved peptide medicines, such as semaglutide and tirzepatide, have been reviewed by the FDA for the uses on their labels, and the labels set out their risks. Compounded peptides are not FDA approved, and the FDA says it does not review compounded drugs for safety, effectiveness or quality before they are marketed. For many peptides sold online, the FDA has said it has little or no safety information in people.
Is BPC-157 safe?
BPC-157 has no FDA-approved product. When the FDA listed it among bulk substances that may present significant safety risks, it said BPC-157 may pose a risk of immunogenicity for certain routes of administration and that it had identified no, or only limited, safety-related information. Since October 2026 an interim HHS policy lets licensed 503A pharmacies compound it on a prescription; HHS says that policy does not grant FDA approval or establish safety and effectiveness.
Are peptide injections safe?
The FDA-approved injectable peptides, such as Wegovy and Zepbound, carry labels that list their risks, including a boxed warning about a risk of thyroid C-cell tumors. For many other injected peptides, the FDA's stated concerns include immunogenicity (an immune reaction to the peptide) and impurities, and it has said it has little or no safety information in people.
Is it safe to buy peptides online for research?
The FDA warns that some products are falsely labeled "for research purposes" or "not for human consumption" and urges consumers not to buy products of unknown quality that may be harmful to their health. A product sold that way is not an approved medicine for people.
Is compounded semaglutide safe?
Compounded semaglutide is not FDA approved, and the FDA says it does not review compounded drugs for safety, effectiveness or quality before they are marketed. The FDA has also received reports of adverse events, some requiring hospitalization, that may be related to dosing errors when patients measured and self-administered compounded GLP-1s.
Sources
- FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of April 22, 2026. Read November 17, 2026.
- FDA: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of October 1, 2026. Read November 17, 2026.
- HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Docket HHS-OASH-2026-0496), Federal Register public inspection copy. Published October 30, 2026.
- Zepbound (tirzepatide) injection, US prescribing information, revised August 2026, DailyMed. Read November 5, 2026.
- Wegovy (semaglutide) injection and Wegovy (semaglutide) tablets, US prescribing information, revised June 2026, DailyMed. Read November 17, 2026.